Cargando…

Glioblastoma pharmacotherapy: A multifaceted perspective of conventional and emerging treatments (Review)

Due to its localisation, rapid onset, high relapse rate and resistance to most currently available treatment methods, glioblastoma multiforme (GBM) is considered to be the deadliest type of all gliomas. Although surgical resection, chemotherapy and radiotherapy are among the therapeutic strategies u...

Descripción completa

Detalles Bibliográficos
Autores principales: Sevastre, Ani-Simona, Costachi, Alexandra, Tataranu, Ligia Gabriela, Brandusa, Corina, Artene, Stefan Alexandru, Stovicek, Olivian, Alexandru, Oana, Danoiu, Suzana, Sfredel, Veronica, Dricu, Anica
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8524703/
https://www.ncbi.nlm.nih.gov/pubmed/34676001
http://dx.doi.org/10.3892/etm.2021.10844
_version_ 1784585532848734208
author Sevastre, Ani-Simona
Costachi, Alexandra
Tataranu, Ligia Gabriela
Brandusa, Corina
Artene, Stefan Alexandru
Stovicek, Olivian
Alexandru, Oana
Danoiu, Suzana
Sfredel, Veronica
Dricu, Anica
author_facet Sevastre, Ani-Simona
Costachi, Alexandra
Tataranu, Ligia Gabriela
Brandusa, Corina
Artene, Stefan Alexandru
Stovicek, Olivian
Alexandru, Oana
Danoiu, Suzana
Sfredel, Veronica
Dricu, Anica
author_sort Sevastre, Ani-Simona
collection PubMed
description Due to its localisation, rapid onset, high relapse rate and resistance to most currently available treatment methods, glioblastoma multiforme (GBM) is considered to be the deadliest type of all gliomas. Although surgical resection, chemotherapy and radiotherapy are among the therapeutic strategies used for the treatment of GBM, the survival rates achieved are not satisfactory, and there is an urgent need for novel effective therapeutic options. In addition to single-target therapy, multi-target therapies are currently under development. Furthermore, drugs are being optimised to improve their ability to cross the blood-brain barrier. In the present review, the main strategies applied for GBM treatment in terms of the most recent therapeutic agents and approaches that are currently under pre-clinical and clinical testing were discussed. In addition, the most recently reported experimental data following the testing of novel therapies, including stem cell therapy, immunotherapy, gene therapy, genomic correction and precision medicine, were reviewed, and their advantages and drawbacks were also summarised.
format Online
Article
Text
id pubmed-8524703
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher D.A. Spandidos
record_format MEDLINE/PubMed
spelling pubmed-85247032021-10-20 Glioblastoma pharmacotherapy: A multifaceted perspective of conventional and emerging treatments (Review) Sevastre, Ani-Simona Costachi, Alexandra Tataranu, Ligia Gabriela Brandusa, Corina Artene, Stefan Alexandru Stovicek, Olivian Alexandru, Oana Danoiu, Suzana Sfredel, Veronica Dricu, Anica Exp Ther Med Review Due to its localisation, rapid onset, high relapse rate and resistance to most currently available treatment methods, glioblastoma multiforme (GBM) is considered to be the deadliest type of all gliomas. Although surgical resection, chemotherapy and radiotherapy are among the therapeutic strategies used for the treatment of GBM, the survival rates achieved are not satisfactory, and there is an urgent need for novel effective therapeutic options. In addition to single-target therapy, multi-target therapies are currently under development. Furthermore, drugs are being optimised to improve their ability to cross the blood-brain barrier. In the present review, the main strategies applied for GBM treatment in terms of the most recent therapeutic agents and approaches that are currently under pre-clinical and clinical testing were discussed. In addition, the most recently reported experimental data following the testing of novel therapies, including stem cell therapy, immunotherapy, gene therapy, genomic correction and precision medicine, were reviewed, and their advantages and drawbacks were also summarised. D.A. Spandidos 2021-12 2021-10-06 /pmc/articles/PMC8524703/ /pubmed/34676001 http://dx.doi.org/10.3892/etm.2021.10844 Text en Copyright: © Sevastre et al. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License (https://creativecommons.org/licenses/by-nc-nd/4.0/) , which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
spellingShingle Review
Sevastre, Ani-Simona
Costachi, Alexandra
Tataranu, Ligia Gabriela
Brandusa, Corina
Artene, Stefan Alexandru
Stovicek, Olivian
Alexandru, Oana
Danoiu, Suzana
Sfredel, Veronica
Dricu, Anica
Glioblastoma pharmacotherapy: A multifaceted perspective of conventional and emerging treatments (Review)
title Glioblastoma pharmacotherapy: A multifaceted perspective of conventional and emerging treatments (Review)
title_full Glioblastoma pharmacotherapy: A multifaceted perspective of conventional and emerging treatments (Review)
title_fullStr Glioblastoma pharmacotherapy: A multifaceted perspective of conventional and emerging treatments (Review)
title_full_unstemmed Glioblastoma pharmacotherapy: A multifaceted perspective of conventional and emerging treatments (Review)
title_short Glioblastoma pharmacotherapy: A multifaceted perspective of conventional and emerging treatments (Review)
title_sort glioblastoma pharmacotherapy: a multifaceted perspective of conventional and emerging treatments (review)
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8524703/
https://www.ncbi.nlm.nih.gov/pubmed/34676001
http://dx.doi.org/10.3892/etm.2021.10844
work_keys_str_mv AT sevastreanisimona glioblastomapharmacotherapyamultifacetedperspectiveofconventionalandemergingtreatmentsreview
AT costachialexandra glioblastomapharmacotherapyamultifacetedperspectiveofconventionalandemergingtreatmentsreview
AT tataranuligiagabriela glioblastomapharmacotherapyamultifacetedperspectiveofconventionalandemergingtreatmentsreview
AT brandusacorina glioblastomapharmacotherapyamultifacetedperspectiveofconventionalandemergingtreatmentsreview
AT artenestefanalexandru glioblastomapharmacotherapyamultifacetedperspectiveofconventionalandemergingtreatmentsreview
AT stovicekolivian glioblastomapharmacotherapyamultifacetedperspectiveofconventionalandemergingtreatmentsreview
AT alexandruoana glioblastomapharmacotherapyamultifacetedperspectiveofconventionalandemergingtreatmentsreview
AT danoiusuzana glioblastomapharmacotherapyamultifacetedperspectiveofconventionalandemergingtreatmentsreview
AT sfredelveronica glioblastomapharmacotherapyamultifacetedperspectiveofconventionalandemergingtreatmentsreview
AT dricuanica glioblastomapharmacotherapyamultifacetedperspectiveofconventionalandemergingtreatmentsreview